Saturday, March 19, 2022 : Issue #1192

TOP STORIES - Diabetes News & Research

An Effective Treatment for Type 1 Using A Blood Pressure Medication

Lipid Profiling Can Predict the Risk of Diabetes and CVD Years Before Onset

Eating Habits and Their Impact on T2D Treatments

Can Caffeine be the Key to Fighting CVD?

Treating CVD with DPP-4 Inhibitors vs. Sulphonylureas Plus Metformin

Youth T2D Has Serious Consequences

Letter from the Editor

It is amazing how full drive-through windows are at coffee shops. It does not matter what time of day; there is always a line. There are people ordering plain coffee, lattes, and dozens of drinks I can’t even spell. What if in the future they could place an order for a CVD blocker?

This may occur sooner than you think, as our intern, Amanda Roberts, PharmD Candidate, Florida A&M University, has found some very interesting data on how caffeine can actually reduce the risk of CVD, and even lower LDL. Check out her feature here.

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief

TOP STORIES - Diabetes News and Research

An Effective Treatment for Type 1 Using A Blood Pressure Medication
Verapamil might serve as a potential breakthrough allowing type one diabetes patients to produce their insulin.

Lipid Profiling Can Predict the Risk of Diabetes and CVD Years Before Onset
The analysis of lipid profiling in the prediction of risk of developing type 2 diabetes and cardiovascular diseases can aid in recommending lifestyle changes and diet before the development of the diseases.

Eating Habits and Their Impact on T2D Treatments
Studies have shown that emotional eating and other eating behaviors could reduce weight loss when taking GLP-1 receptor agonists.

Can Caffeine be the Key to Fighting CVD?
Studies have found that average levels of moderate caffeine intake are related to lower cardiovascular risk.

Treating CVD with DPP-4 Inhibitors vs. Sulphonylureas Plus Metformin
New retrospective study results compare the two most primarily prescribed antidiabetic medication classes in addition to metformin to determine the impact on the incidence of CV events in patients with T2DM.

Youth T2D Has Serious Consequences
According to the research presented by Dr. Petter Bjornstad from the University of Colorado Anschutz Medical Campus, the risk of microvascular complications increases by the time of young adulthood in patients who have diabetes in youth.

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this newsletter:

Betsy Adegborioye, PharmD Candidate 2022, South College School of Pharmacy

Janet Falade, PharmD Candidate, South College School of Pharmacy

Kmeone Kingdom, MPH, PharmD Candidate, South College School of Pharmacy

Amanda Roberts, PharmD Candidate, Florida A&M University, College of Pharmacy and Pharmaceutical Sciences Institute of Public Health

Alexa Rodriguez, PharmD Candidate 2022, University of South Florida, Taneja College of Pharmacy

Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
www.diabetesincontrol.com

Diabetes In Control
2093 Philadelphia Pike #8370
Claymont, DE, 19703, United States

DiabetesInControl.com | Contact Us
Subscription Center | Update Profile
Unsubscribe